Drug intelligence / Profile preview

GenSciP181

Development stage: Preclinical
Lead developer: Changchun GeneScience Pharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravitreal, Ophthalmic

Overview

GenSciP181 is a preclinical-stage small interfering RNA (siRNA) candidate being developed by GeneScience Pharmaceuticals (GenSci) and North America Genescience for the treatment of dry age-related macular degeneration (dAMD). The therapeutic is designed to target an undisclosed molecular target and is formulated using GenSci's non-hepatic siRNA delivery platform, which is engineered to overcome the traditional limitations of siRNA therapies by enabling targeted delivery to extrahepatic tissues such as the eye.

Beyond the preview

Go deeper on GenSciP181.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenSciP181.

Explore the full profile